J. Heyward Hull
Geen lopende functies
Profiel
Dr. Hull has been senior vice president, development and regulatory affairs since March 2000.
From 1978 to 1995, Dr. Hull held positions of increasing responsibility at Burroughs Wellcome Co., a pharmaceutical company, including director of cardiovascular medicine.
From 1995 to 2000, Dr. Hull held senior management positions at Quintiles Transnational Corp., a provider of global contract product development and commercialization services, including group vice president.
Dr. Hull currently serves as an adjunct clinical professor at the University of North Carolina School of Pharmacy.
Dr. Hull received his doctorate in pharmacy from the University of North Carolina, Chapel Hill.
Eerdere bekende functies van J. Heyward Hull
| Bedrijven | Functie | Einde |
|---|---|---|
Neusentis, Inc.
 Neusentis, Inc. Pharmaceuticals: MajorHealth Technology Neusentis is a biopharmaceutical company, which is focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. The company has developed an integrated technology platform that allows for the efficient discovery of drug leads. The firm is conducting research and development activities in a number of disease areas, including epilepsy, pain and inflammation. Icagen has two clinical stage programs in epilepsy and pain. The company was formerly known as Icagen, Inc. It was founded by Andre L. Lamotte and P. Kay Wagoner on November 23, 1992 and is headquartered in Durham, NC. | Corporate Officer/Principal | 17-05-2006 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 1 |
|---|---|
Neusentis, Inc.
Neusentis, Inc. Pharmaceuticals: MajorHealth Technology Neusentis is a biopharmaceutical company, which is focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. The company has developed an integrated technology platform that allows for the efficient discovery of drug leads. The firm is conducting research and development activities in a number of disease areas, including epilepsy, pain and inflammation. Icagen has two clinical stage programs in epilepsy and pain. The company was formerly known as Icagen, Inc. It was founded by Andre L. Lamotte and P. Kay Wagoner on November 23, 1992 and is headquartered in Durham, NC. | Health Technology |
